RO6871765

RO6871765 is a **small molecule agonist of the toll-like receptor 7 (TLR7)**, developed for its immune-stimulating effects, particularly to augment antiviral innate immune responses. It is the **active metabolite** of the oral prodrug RO6870868. TLR7 agonists, including RO6871765, have been investigated mainly for the potential treatment of **chronic hepatitis B infection**. Mechanistically, RO6871765 binds and activates TLR7, leading to the production of interferons and stimulating the innate immune system[1][3][5]. In clinical studies, RO6871765 (measured after administration of its prodrug) showed dose-dependent pharmacodynamics consistent with TLR7 agonism, and a safety profile characterized mainly by mild, transient, flu-like symptoms[1][3]. RO6871765 itself has been used in ex vivo immune stimulation assays and in early-phase clinical studies.